FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to the non-viral vector — polyplex, and can be used in medicine. The invention makes it possible to obtain a polymer conjugate consisting of a linear polyethyleneimine covalently bound to one or more fragments of polyethylene glycol (PEG), with each PEG fragment conjugated by a linker with a targeting fragment capable of binding to a cancer antigen.
EFFECT: present invention is capable of binding and condensing nucleic acid molecules — DNA or RNA-and serving as a non-viral vector for the targeted delivery of therapeutic agents to the cells/tissues of the body of a potential patient suffering from prostate cancer or other types of cancer whose cells overexpress EGFR or HER2, for the implementation of gene therapy of these diseases.
29 cl, 19 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| AMATOXIN DERIVATIVES | 2014 |
|
RU2695370C2 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| ANTIBODY-DRUG CONJUGATE LOADED WITH BINARY TOXINS AND ITS USE | 2021 |
|
RU2795148C2 |
| MULTISPECIFIC ANTIBODIES, THEREOF ANALOGUES, COMPOSITIONS AND METHODS | 2010 |
|
RU2580038C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
| MOLECULAR STRUCTURES WITH TARGETING AND EFFECTOR ELEMENTS | 2016 |
|
RU2696378C2 |
